Related Experiment Videos
The development of VIP-ellipticine conjugates
Terry W Moody1, Gregory Czerwinski, Nadia I Tarasova
1Department of Health and Human Services, NCI Office of the Director, CCR, Building 31, Room 3A34, 31 Center Drive, Bethesda, MD 20892, USA. moodyt@mail.nih.gov
Regulatory Peptides
|November 3, 2004
Summary
Vasoactive intestinal peptide (VIP)-ellipticine (E) conjugates show cytotoxicity against lung cancer cells. These VIP-E conjugates are internalized via VPAC1 receptor-mediated endocytosis, delivering cytotoxic ellipticine into cancer cells.
Area of Science:
- Oncology
- Molecular Pharmacology
- Cell Biology
Background:
- Vasoactive intestinal peptide (VIP) receptors are overexpressed in various human cancers, including lung cancer.
- Ellipticine (E) is a potent cytotoxic alkaloid with anticancer properties.
- Targeted drug delivery systems aim to enhance the efficacy of chemotherapeutic agents while minimizing systemic toxicity.
Purpose of the Study:
- To investigate the cytotoxic mechanism of VIP-ellipticine (E) conjugates in human lung cancer cells.
- To determine the role of VPAC1 receptor-mediated endocytosis in the cellular uptake and efficacy of VIP-E conjugates.
- To evaluate the potential of VIP-E conjugates as a targeted therapy for lung cancer.
Main Methods:
- Synthesis and characterization of VIP-alanyl-leucyl-alanyl-leucyl-alanine (ALALA)-E and VIP-leucyl-alanyl-leucyl-alanine (LALA)-E conjugates.
- Assessment of VIP-E conjugate binding to NCI-H1299 lung cancer cells and inhibition of (125)I-VIP binding.
- Measurement of intracellular cyclic adenosine monophosphate (cAMP) levels following VIP-E conjugate treatment.
- Evaluation of cellular internalization, cytotoxicity, and growth inhibition using radiolabeled conjugates, trypan blue exclusion, and [3H]-thymidine uptake assays.
Main Results:
- VIP-ALALA-E and VIP-LALA-E inhibited (125)I-VIP binding to NCI-H1299 cells with IC50 values of 0.5 and 0.1 microM, respectively.
- VIP-ALALA-E and VIP-LALA-E induced cAMP elevation in NCI-H1299 cells with ED50 values of 0.7 and 0.1 microM.
- Radiolabeled VIP-LALA-E was internalized and delivered cytotoxic E into NCI-H1299 cells, inhibiting cell growth and viability.
- Cell viability decreased significantly after 3 days of VIP-LALA-E treatment, as evidenced by trypan blue exclusion and reduced [3H]-thymidine uptake.
Conclusions:
- VIP-E conjugates exhibit potent cytotoxicity against human lung cancer cells.
- The internalization of VIP-E conjugates occurs via VPAC1 receptor-mediated endocytosis.
- VIP-E conjugates represent a promising targeted therapeutic strategy for lung cancer treatment.